
Life Sciences
BridgeBio to Present Phase 3 Encaleret Data at Boston Bone Meeting
The company's results in autosomal dominant hypocalcemia type 1 are scheduled for two oral presentations on October 11 at the Boston gathering.
Boston Business Watch reported on BridgeBio Pharma, Inc. on October 7, 2026.
October 7, 2026
BridgeBio Pharma, Inc. said on October 6, 2026 that it will present further results from its Phase 3 CALIBRATE study of encaleret at the annual meeting of the American Society for Bone and Mineral Research, held in Boston from October 9 to 12, 2026.

Life Sciences
The company's results in autosomal dominant hypocalcemia type 1 are scheduled for two oral presentations on October 11 at the Boston gathering.